Form 4: BioAge Labs CFO Exercises Stock Options

BioAge Labs Chief Financial Officer Dov A. Goldstein exercised options to acquire 3,542 shares of common stock.

Summary

• CFO Dov A. Goldstein exercised stock options for 3,542 shares of BioAge Labs common stock.
• The transaction occurred on April 23, 2026, at an exercise price of $4.38 per share.
• Following the transaction, the reporting person holds 36,575 shares of common stock directly.
• The remaining derivative securities (stock options) held by the reporting person total 155,833 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard administrative exercise of vested employee stock options.

Positives

• Internal alignment as the CFO increases direct equity ownership in the company.

Negatives

• None identified; this is a routine exercise of vested equity compensation.

Risks

• None identified; this is a standard regulatory disclosure of insider equity activity.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine equity exercises by C-suite executives are standard corporate practice and generally reflect the ongoing vesting of compensation packages rather than specific market sentiment.

Comparison to Industry Standards

• The transaction follows standard SEC reporting requirements for executive compensation.
• The vesting schedule (1/48th monthly) is consistent with typical biotech industry equity incentive plans.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine exercise of existing equity compensation.

Next Steps

• Continued service by the reporting person to satisfy remaining vesting requirements for outstanding options.

Key Dates

Keywords

BioAge Labs, BIOA, Form 4, Insider Trading, Stock Options, CFO